Abstract
2011 Background: Conventional therapies for GBM fail to target tumor cells exclusively. Immunologic targeting of tumor- specific gene mutations may allow more precise eradication of neoplastic cells. The epidermal growth factor receptor variant III (EGFRvIII) is a consistent and immunogenic mutation that is not expressed in any normal tissues, but is widely expressed in GBMs and other neoplasms making it an attractive target for active immunotherapy. Methods: A phase II multicenter clinical trial was undertaken to assess the immunogenicity and efficacy of an EGFRvIII-specific peptide vaccine in patients with newly-diagnosed, EGFRvIII+ GBM in combination with simultaneous standard or continuous temozolomide (TMZ). After resection and radiation/TMZ (75 mg/m2/d), consecutive cohorts received subsequent monthly cycles of 200 mg/m2 (N=13) or continuous 100 mg/m2 (N=8) TMZ simultaneous with intradermal vaccinations with an EGFRvIII-specific peptide (PEPvIII) conjugated to keyhole limpet hemocyanin (KLH) until t...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call